Introduction, background and rationale
The control of blood pressure in hypertensive patients from different ethnic groups varies with the class of drug used, probably mediated by genetic and environmental factors. 1 Characterisation of these differences may help the clinician in their choice of initial therapy, although the differences are unlikely to be such that whole classes of agents are excluded, particularly with double or triple therapy. 2 Most evidence on ethnic differences comes from studies of African American men, with the largest study 3 showing significant differences in response to mono-therapy between blacks and whites; with the best response to a calcium channel blocker or a thiazide (in older black patients). The response of black South Africans to antihypertensive agents is reviewed elsewhere. 4 Smaller trials of double therapy also suggest better control with calcium channel blockers in black Kenyan patients. 5 We do not know if this differential hypotensive response is also true for black patients (African or Afro-Caribbean) in the United Kingdom. Nor do we know if some agents are more effective in the UK's other large ethnic minority, South Asians. Two trials in India and South Africa 6, 7 did not find any differences, but their sample sizes (24 and 26 respectively) cannot exclude a Type II error. The results of these studies, such as Materson's, 3 together with the apparent differences in pathophysiology of hypertension between ethnic groups, led us to expect differences in response to the ASCOT study drugs by ethnic group. For example, lower renin levels in blacks may account for a poorer hypotensive response to beta-blockers and ACEinhibitors in the context of mono-therapy. 8 Differences in response to antihypertensive treatment may have a genetic component 9, 10 but is likely to be influenced by other factors, which are unevenly distributed between ethnic groups, such as socioeconomic status, diet, obesity and alcohol use.
There are other compelling reasons for identifying the ethnicity of trial participants. Other sub-studies (eg, left ventricular mass and geometry, genetic analysis, ambulatory blood pressure monitoring, renal status) will also require information on the ethnic identity of participants. Finally, adverse effects may differ between ethnic groups receiving the same agents. Although there is not enough power to detect differences in cardiovascular events or deaths between ethnic groups, analysis of outcomes by ethnic groups may show trends requiring further investigation.
This sub-study is based on five centres (St Bartholomew's, Leicester, St Mary's, St George's, Manchester) recruiting participants from areas with substantial black (Afro-Caribbean and African) and/or South Asian (Bangladeshi, Pakistani and Indian) communities, with other urban centres also contributing participants from ethnic minorities. These communities are at high risk of stroke (black) and coronary heart disease (South Asian) and effective control of hypertension is therefore a major treatment issue for these groups in general practice. We have the opportunity within ASCOT's treatment protocol to test for differences in response to monotherapy and dual therapy from three ethnic groupings: whites, blacks and South Asians. (For the purpose of this sub-study, 'white' refers to white people of British descent, 'black' refers to people of African or Afro-Caribbean descent, and 'South Asian' refers to people of Bangladeshi, Pakistani or Indian descent.) Socioeconomic status (SES) is a potential confounding variable 11, 12 and therefore we are recording this alongside ethnic identity. However SES will not necessarily have the same meaning among men and women and in different ethnic groups. Within the ASCOT data set, other potential confounders of ethnicity will also be recorded for participants recruited to the trial: body mass index, alcohol consumption and smoking habits.
The ethnicity of participants in ASCOT will be determined by their responses to a self-assigned ethnicity question and the country of birth of the subject and their parents. These questions are a component of the cohort cardiovascular risk questionnaire. 13 Combined with information on antihypertensive medication and blood pressure measurements from the ASCOT data set, we will be able to determine if there are any clinically important differences in blood pressure response to first-line agents in ASCOT by ethnic group. It will also allow analysis of differences in response to dual therapy by ethnic group, if sufficient numbers are receiving this treatment as per protocol.
Objectives
To test four null hypotheses about the effect of mono-therapy and, if possible, dual therapy. That 1-year after commencing treatment: (a) The same proportion of black participants will have satisfactory blood pressure control (satisfactory control = target pressures in ASCOT (ie, Ͻ140 mm Hg and Ͻ90 mm Hg for non-diabetics; Ͻ130 mm Hg and Ͻ80 mm Hg for diabetics), on amlodipine or atenolol mono-therapy. (b) The same proportion of South Asian participants will have satisfactory control on amlodipine or atenolol mono-therapy. (c) The same proportion of black participants, South Asian participants and white participants will have satisfactory control on amlodipine. (d) The same proportion of black participants, South Asian participants and white participants will have satisfactory control on atenolol.
The sub-study will also analyse mean blood pressure levels and changes in blood pressure by ethnic group in participants who require dual or triple therapy. If sufficient numbers of participants require dual therapy by the study protocol, as may be implied from the stringency of the blood pressure inclusion criteria, we will be able to test the above hypotheses for dual therapy.
Methods
The ethnicity of a participant is determined by their response to specific questions in the self-administered cohort cardiovascular risk questionnaire, which is completed at their screening appointment. Individuals screened prior to commencement of the sub-study will be invited to take part retrospectively. As the ethnicity sub-study questions are a component of the cohort sub-study, ethical approval, consent details, number of subjects involved and recruitment details are the same and are described in the accompanying paper. 13 There is a potential for a biased interpretation of blood pressure readings by trial clinicians since they are blind neither to the ethnicity of the participant, nor to the hypotensive agent. This bias is reduced by electronic measurement of blood pressure by OMRON device, with a printed record, which are used throughout the study. 14 The classification of ethnic groups is controversial, particularly the merging of diverse groups under broad headings. 15 The options in our questionnaire have been piloted at the St Bartholomew's ASCOT centre and have proved acceptable to participants in East London. The large categories for analysis are necessitated by power considerations, although the more precise ascertainment of ethnicity will allow exploratory comparisons of mean blood pressure response of smaller groups (eg African vs Afro-Caribbean), although these are still broad categories. Socioeconomic status, a potential confounding variable 12 will be assessed using income and age at leaving full time education, occupation and house ownership. 16 The power assumptions for this sub-study are as follows: (a) The five centres with substantial ethnic minorities will recruit 5000 participants. (b) The proportion of black and South Asian participants recruited will be the same proportion as in the adult population over 40 years old (see Table 1 ). This balances potential under-recruitment from ethnic minorities with over-representation on hypertension registers and in hospital clinics because of increased prevalence. (c) That an important difference in mono-therapy response rate, between agents and between ethnic groups, is from 50 to 75% of satisfactory control. (The second analysis of the VA Cooperative study showed this difference between diltiazem and atenolol in black men.
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) Based on these assumptions, 85 participants are required in each treatment group from each ethnic group to detect a response rate difference from 50% to 75%, with 90% power at 5% significance level. In order to allow for comparisons being made in the three ethnic groups this is increased to 99 in each group. Even with the conservative estimate of numbers from census data, the study will be able to recruit more than the 200 participants/ethnic group required for this analysis. In fact, with the higher prevalence of hypertension in the South Asian and black communities, it is likely that a larger number of participants from ethnic minorities will be recruited, allowing the detection of smaller differences in blood pressure control between groups.
Analysis of the proportion of participants adequately controlled at 1 year will be carried out using logistic regression with interactions to test whether the treatment effect is different between ethnic groups. Additional analysis of this response to treatment at 1 year will use logistic regression with possible confounding factors including gender, age, socioeconomic status, body mass index, and alcohol consumption included as explanatory variables. Repeated measures analysis of variance will be used to compare mean blood pressures by ethnic group for single agents or combinations of agents.
Discussion
If the blood pressure response rates to mono-therapy in ASCOT are similar to those observed in Materson's trial, there are unlikely to be sufficient black and South Asian participants requiring dual therapy to detect important differences in response between ethnic groups or between agents within ethnic groups. If a higher proportion of participants require dual therapy than expected, we predict from the census figures that there will be sufficient participants to detect differences in satisfactory control for dual therapy between agents and between ethnic groups. This may occur as a result of the demanding systolic treatment targets in ASCOT and/or the trial recruits a larger number of participants from black and South Asian minorities. For example, in one American study of blood pressure control in inner city clinics with multi-ethnic, low income participants, 36% were on dual or triple therapy, but of those on mono-therapy, 45% had a systolic blood pressure Ͼ140 mm Hg. 18 The ethnicity sub-study was designed when there were substantially fewer centres participating in ASCOT. The addition of a number of subsequent sites (for example, Birmingham, Rugby, Nuneaton, Greenwich) with populations of both black and South Asian people should increase the number of these ethnic minorities recruited into ASCOT and therefore this sub-study. At the time of writing, the 6210 participants randomised to date can be broken down by 'race' as recorded on the screening case record form, as shown in Table 2 . Compared to our predicted number of participants from these ethnic groups (Table 1) , we will exceed the number of black participants and are on target for reaching the required number of South Asian participants for the ethnicity sub-study. The information gained from the ethnicity questions will also provide much more detailed information on these participants' ethnic identity.
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